Ovarian Cancer Screening

Transvaginal ultrasound and CA-125 testing for ovarian cancer detection

Ovarian cancer is often called the silent killer because symptoms appear late. While no single screening test is definitive for ovarian cancer in average-risk women, a combination of CA-125 blood testing and transvaginal ultrasound provides the most useful surveillance tool, particularly for higher-risk patients.

Screening is strongly recommended for women with BRCA mutations, strong family history of ovarian or breast cancer, or Lynch syndrome, and offered to other women as part of comprehensive gynaecological health monitoring.

Key Benefits

CA-125 and ultrasound combination provides best available screening
Identifies ovarian masses warranting further investigation
Particularly effective for high-risk and hereditary cancer patients
Results reviewed by gynaecological oncology-experienced team

Is This Treatment Right For You?

Women with BRCA1/2 mutations or strong family history
Those with Lynch syndrome
Women with unexplained pelvic pain or bloating needing assessment

What to Expect

Gynaecological Consultation

Family history and risk factors reviewed.

CA-125 Blood Test

Blood draw for CA-125 marker measurement.

Transvaginal Ultrasound

Ovarian morphology and volume assessed by ultrasound.

Results & Referral

Results interpreted; gynaecological oncology referral arranged for any concerns.

Recovery & Aftercare

No downtime — screening involves blood draw and non-invasive ultrasound.

Frequently Asked Questions

Is CA-125 a reliable cancer marker?

CA-125 is elevated in most ovarian cancers but also in benign conditions; it is most useful as part of a combined assessment rather than as a standalone test.

How often should high-risk women be screened?

Every 6–12 months for women with BRCA mutations or hereditary risk; your gynaecologist will advise the appropriate interval for your risk level.